Shannon C. Trotter, DO, FAOCD, a certified dermatologist at Dermatologists of the Central States in Ohio, discusses immunotherapy options for the treatment of advanced cutaneous squamous cell carcinoma (cSCC) and why dermatologists should remain involved in the care process even after patients are referred to oncology. In an interview with HCPLive, Trotter highlights the active role dermatologists should play in this process, as well as the immunotherapeutic options for advanced cSCC, the anticipated Medicare cuts, and the future of artificial intelligence in skin cancer care.[^1]
Trotter also evaluated the anticipated Medicare cuts in terms of patient access. Older adults who are more affected by squamous cell carcinoma may experience delays in diagnosis and treatment. With early detection, the survival rate for melanoma is approximately 100%; Trotter added that the dermatology community has called for a petition against the cuts. Looking ahead, Trotter highlighted augmented intelligence, which combines artificial intelligence with physician reasoning, as a significant opportunity in both melanoma and non-melanoma squamous cell carcinoma. New diagnostic tools may enable earlier detection. Genomic profiling can provide prognostic information, either alone or in conjunction with artificial intelligence, and may guide treatment decisions in the future.[1]: Schlesinger TE, Trotter SC. Seminar-in-depth: deep dive on cutaneous squamous cell carcinoma and the latest in immunotherapy. Presentation: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Bu gelişme hakkında düşüncelerinizi, donanım deneyimlerinizi veya sorularınızı Community Forumumuzda paylaşın.
読者コミュニティ
0 件のレビュー
ご自身の体験を共有できます。診断、治療、緊急事態についてはコメント欄ではなく医療専門家にご相談ください。